CA2665141C - Composition comprising crustacean gastrolith components and its use - Google Patents

Composition comprising crustacean gastrolith components and its use Download PDF

Info

Publication number
CA2665141C
CA2665141C CA2665141A CA2665141A CA2665141C CA 2665141 C CA2665141 C CA 2665141C CA 2665141 A CA2665141 A CA 2665141A CA 2665141 A CA2665141 A CA 2665141A CA 2665141 C CA2665141 C CA 2665141C
Authority
CA
Canada
Prior art keywords
caco3
chitin
pharmaceutical formulation
organic matter
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2665141A
Other languages
English (en)
French (fr)
Other versions
CA2665141A1 (en
Inventor
Amir Sagi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Ben Gurion University of the Negev Research and Development Authority Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ben Gurion University of the Negev Research and Development Authority Ltd filed Critical Ben Gurion University of the Negev Research and Development Authority Ltd
Publication of CA2665141A1 publication Critical patent/CA2665141A1/en
Application granted granted Critical
Publication of CA2665141C publication Critical patent/CA2665141C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
CA2665141A 2006-10-05 2007-10-07 Composition comprising crustacean gastrolith components and its use Active CA2665141C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL178495A IL178495A (en) 2006-10-05 2006-10-05 Use of cancerous gastric components or artificial calcium containing carbonate, chitin and polypeptide preparations to treat calcium metabolism-related or calcium-signaling conditions
IL178495 2006-10-05
PCT/IL2007/001211 WO2008041236A2 (en) 2006-10-05 2007-10-07 Composition comprising crustacean gastrolith components, calcium carbonate and its use

Publications (2)

Publication Number Publication Date
CA2665141A1 CA2665141A1 (en) 2008-04-10
CA2665141C true CA2665141C (en) 2015-03-24

Family

ID=39153987

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2665141A Active CA2665141C (en) 2006-10-05 2007-10-07 Composition comprising crustacean gastrolith components and its use

Country Status (14)

Country Link
US (2) US20100098774A1 (https=)
EP (1) EP2068891B1 (https=)
JP (1) JP2010505818A (https=)
CN (1) CN101563091A (https=)
AU (1) AU2007303786B2 (https=)
CA (1) CA2665141C (https=)
CY (1) CY1114930T1 (https=)
DK (1) DK2068891T3 (https=)
ES (1) ES2439741T3 (https=)
IL (1) IL178495A (https=)
PL (1) PL2068891T3 (https=)
PT (1) PT2068891E (https=)
SI (1) SI2068891T1 (https=)
WO (1) WO2008041236A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257750B2 (en) * 1999-04-30 2012-09-04 Kibow Biotech, Inc. Calcium carbonate compositions for preventing or treating hyperphosphatemia
PL2211873T3 (pl) 2007-10-22 2013-01-31 Amorphical Ltd Stabilny amorficzny węglan wapnia wchodzący w skład fosforylowanych aminokwasów
EP2790710B1 (en) 2011-12-13 2020-08-26 Amorphical Ltd. Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders
WO2014024191A1 (en) 2012-08-07 2014-02-13 Amorphical Ltd. Method for producing stabilized amorphous calcium carbonate
JP2016507553A (ja) * 2013-02-11 2016-03-10 アモーフィカル リミテッド． 骨成長を促進する非晶質炭酸カルシウム
CN103417635B (zh) * 2013-08-15 2015-05-20 张荣惠 接骨药
EP3174409A4 (en) 2014-07-31 2018-01-17 Amorphical Ltd. Encapsulated amorphous calcium carbonate compositions
US12121538B2 (en) 2015-06-04 2024-10-22 Amorphical Ltd. Compositions of amorphous calcium carbonate for inhalation, sublingual or buccal administration
HK1253702A1 (zh) * 2015-06-04 2019-06-28 艾玛菲克有限公司 用聚磷酸/聚磷酸酯/聚磷酸盐或双膦酸/双膦酸酯/双膦酸盐稳定的无定形碳酸钙
AU2016374162A1 (en) * 2015-12-14 2018-04-19 Nestec S.A. Nutritional compositions and infant formulas to promote myelination in the brain
MY197734A (en) * 2015-12-14 2023-07-12 Nestle Sa Nutritional compositions and infant formula for promoting de novo myealination
US11478011B2 (en) 2015-12-14 2022-10-25 Societe Des Produits Nestle S.A. Nutritional compositions and infant formula for promoting de novo myealination
JP6873389B2 (ja) 2016-01-18 2021-05-19 アモーフィカル リミテッド． 神経学的、筋肉、および不妊の疾患または症状の治療のための安定化無定形炭酸カルシウム
ES3052833T3 (en) 2016-01-18 2026-01-15 Amorphical Ltd Stabilized amorphous calcium carbonate as a supplement for cell culture media
JP7152785B2 (ja) * 2016-10-25 2022-10-13 アモーフィカル リミテッド． 白血病治療のための非晶質炭酸カルシウム
IL289237B2 (en) 2019-07-23 2026-03-01 Amorphical Ltd Amorphous calcium carbonate for improving athletic performance

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237147A (en) 1974-01-04 1980-12-02 Monsanto Company Stabilized amorphous calcium carbonate
US4199496A (en) * 1974-09-05 1980-04-22 Johnson Edwin L Process for the recovery of chemicals from the shells of crustacea
US5886012A (en) * 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers
US20060165784A1 (en) * 1997-05-06 2006-07-27 Zhao Jin R Calcium supplement
US20030077604A1 (en) * 2000-10-27 2003-04-24 Yongming Sun Compositions and methods relating to breast specific genes and proteins
JP2002205947A (ja) * 2000-12-11 2002-07-23 Chafflose Corporation 水虫治療薬
EP1416916B1 (en) * 2001-08-16 2007-10-17 Cmp Therapeutics Limited Chitin microparticles and their medical uses
JP2004081739A (ja) * 2002-08-29 2004-03-18 Mitsuru Akashi ハイドロキシアパタイト−ポリマー複合材料の止血用組成物
WO2005025581A1 (fr) * 2003-09-17 2005-03-24 Third Military Medical University, Chinese People's Liberation Army, P.R. Of China Utilisation de la n-acetyl-d-aminoglycosamine pour la preparation de medicaments de traitement du cancer et des metastases
CA2567972C (en) * 2004-05-26 2015-07-28 Ben-Gurion University Of The Negev Research And Development Authority Orally-administrable compositions comprising stable amorphous calcium carbonate
WO2006043966A2 (en) * 2004-10-15 2006-04-27 University Of Tennessee Research Foundation Methods for inducing apoptosis in adipocytes

Also Published As

Publication number Publication date
CY1114930T1 (el) 2016-12-14
WO2008041236A3 (en) 2009-05-14
EP2068891A2 (en) 2009-06-17
ES2439741T3 (es) 2014-01-24
US20130122117A1 (en) 2013-05-16
CA2665141A1 (en) 2008-04-10
US20100098774A1 (en) 2010-04-22
AU2007303786A1 (en) 2008-04-10
IL178495A0 (en) 2007-02-11
DK2068891T3 (da) 2014-01-13
PL2068891T3 (pl) 2014-03-31
EP2068891B1 (en) 2013-09-25
IL178495A (en) 2014-12-31
CN101563091A (zh) 2009-10-21
AU2007303786B2 (en) 2012-07-26
SI2068891T1 (sl) 2014-02-28
PT2068891E (pt) 2013-12-27
JP2010505818A (ja) 2010-02-25
WO2008041236A2 (en) 2008-04-10
US8728533B2 (en) 2014-05-20

Similar Documents

Publication Publication Date Title
CA2665141C (en) Composition comprising crustacean gastrolith components and its use
KR101497003B1 (ko) 인산염 흡착제
CN101559218B (zh) 一种具有增加骨密度功能的组合物
CN104116022A (zh) 用于改善妇女更年期综合症的复合保健食品及其制备方法
CN107349333A (zh) 具有增加骨密度功效的组合物及其制备方法和应用
CN104736161A (zh) 预防和治疗非典型性骨质疏松的制剂和方法
CN101513484A (zh) 一种预防和治疗骨质疏松的药物组合物及其制备方法
CN106177908A (zh) 一种具有增加骨密度功能的组合物及其制备方法
CN114366764A (zh) 一种提高人体免疫力，预防和/或治疗骨关节炎的组合物
EP2944314B1 (en) Preparation for treating arthritis and arthrosis
JP3248170B2 (ja) コンドロイチン硫酸蛋白複合体含有食品
CN102000110A (zh) 一种用于预防或治疗骨和关节疾病的组合物及其制备方法
CN113425846A (zh) 一种改善骨密度、延缓骨及关节老化的配方
HU200933B (en) Process for producing pharmaceutical composition for profilacting and treating osteoporosis
CN110384241A (zh) 一组有助于骨健康的组合物及其制备方法
CN100387244C (zh) 抗骨质疏松症组合物
WO2026047691A1 (en) Synergistic nutraceutical composition to improve calcium absorption
CN103316021B (zh) 一种骨化三醇和含钙物组成的药物组合物及用途
CN106173614A (zh) 一种具有增加骨密度功能的组合物及其制备方法
WO2026049684A1 (en) Calcium-containing food supplement
WO2019160500A1 (en) Use of ferrous amino acid chelate to increase calcium absorption and bone mass, and to treat osteoporosis
CN117064912A (zh) 一种矿物离子组合物及其在制备对痛症具有治疗作用的产品中的应用
CN120616124A (zh) 一种具有补骨健骨作用的药食同源营养组合物及其制备方法及应用
CN102406177B (zh) 一种壮骨的保健品
CN101444552A (zh) 治疗骨质疏松的中药制剂

Legal Events

Date Code Title Description
EEER Examination request
H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250410